ABBV-319

DRUG2 trials

Sponsors

AbbVie

Conditions

Chronic Lymphocytic LeukemiaDiffuse Large B-Cell LymphomaDry Eye SyndromeFollicular LymphomaSystemic Lupus Erythematosus

Phase 1

A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)

Active, not recruitingNCT05512390

AbbVieChronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma

Start: 2023-04-26End: 2027-02-01Updated: 2026-08-28

A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants With Systemic Lupus Erythematosus (SLE), Sjogren's Disease (SjD) and Rheumatoid Arthritis (RA)

RecruitingNCT06977724

AbbVieDry Eye Syndrome, Systemic Lupus Erythematosus

Start: 2025-08-26End: 2029-03-01Target: 36Updated: 2026-08-10

Related Papers

Abstract PO-006: ABBV-319: A CD19–targeting glucocorticoid receptor modulator antibody-drug conjugate therapy for B-cell malignancies

Blood Cancer Discovery2024-06-19

Abstract ND01: ABBV-319: A first-in-class Glucocorticoid Receptor Modulator (GRM) agonist ADC for the treatment of B-cell malignancies

Cancer Research2023-05-29